Physician profile
Dena K Reddick
NPI 1588763395
$7,420.52
in general payments reported to CMS, 2019-2025
42 companies · $1,632 in 2025
The $1,632 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,722 · 2022: $1,617 · 2023: $1,385 · 2024: $1,065 · 2025: $1,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,081.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $949.33 | 2021-2025 | |
| Lilly USA, LLC | $815.81 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $793.00 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $712.93 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $684.28 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $598.27 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $348.31 | 2021-2024 | Xarelto |
| Amgen INC. | $274.35 | 2021-2025 | Evenity, Prolia, Repatha |
| Merck Sharp & Dohme LLC | $255.71 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $253.43 | 2021-2025 | Xifaxan |
| Pfizer INC. | $228.95 | 2021-2025 | |
| Radius Health, INC. | $197.40 | 2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $142.30 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $113.44 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $105.91 | 2023-2025 | Cologuard Collection Kit |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dena Reddick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.